Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (191-200 of 421) with videos related to

Pageof 43
Sort By:
Blood Advances|September 29, 2021
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.
American Journal of Hematology|September 16, 2024
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 yearsMichael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Cancer|March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 5, 2002
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantationEdwin P Alyea, Edie Weller, David C Fisher, et al.
Leukemia|May 29, 2020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 yearsAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Alice Mims, et al.
Blood Advances|January 15, 2026
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 CriteriaShai Shimony, Yating Wang, Angel M Cronin, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
The Lancet. Haematology|June 7, 2016
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysisAreej El-Jawahri, Tanya Keenan, Gregory A Abel, et al.
Pageof 43

Showing results (191-200 of 421) with videos related to

Sort By:
Pageof 43
Blood Advances|September 29, 2021
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.
American Journal of Hematology|September 16, 2024
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 yearsMichael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Cancer|March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 5, 2002
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantationEdwin P Alyea, Edie Weller, David C Fisher, et al.
Leukemia|May 29, 2020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 yearsAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Alice Mims, et al.
Blood Advances|January 15, 2026
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 CriteriaShai Shimony, Yating Wang, Angel M Cronin, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
The Lancet. Haematology|June 7, 2016
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysisAreej El-Jawahri, Tanya Keenan, Gregory A Abel, et al.
Pageof 43